Validation of Biomarker-Based ABCD Score in Atrial Fibrillation Patients with a Non-Gender CHA<sub>2</sub>DS<sub>2</sub>-VASc Score 0–1: A Korean Multi-Center Cohort — Moonki Jung (2022) | RDL Network
Validation of Biomarker-Based ABCD Score in Atrial Fibrillation Patients with a Non-Gender CHA<sub>2</sub>DS<sub>2</sub>-VASc Score 0–1: A Korean Multi-Center Cohort
Article 2022 en
Authors
MJ
Moonki Jung
KB
Kyeongmin Byeon
KK
Ki‐Woon Kang
Abstract
1 min read
The biomarker-based ABCD score demonstrated improved stroke risk stratification in AF patients with non-gender CHA<sub>2</sub>DS<sub>2</sub>-VASc score 0-1. Furthermore, NOAC with an ABCD score ≥1 was associated with significantly lower stroke rate in AF patients with non-gender CHA<sub>2</sub>DS<sub>2</sub>-VASc score 0-1.
Professor Gregory Lip, Richard E. Murphy, Farhad Sahiar, Amol D. Dhamane, Mauricio Ferri, Patrick Hlavacek, Madison T Preib, Allison Keshishian, Cristina Russ, Lisa Rosenblatt, Steve Deitelzweig
Seung Yong Shin, Sang Jin Han, Jin Seok Kim, Sung Il Im, Jaemin Shim, Jinhee Ahn, Eun Mi Lee, Yae Min Park, Jun Hyung Kim, Professor Gregory Lip, Hong Euy Lim
Discussion(0)
No comments yet. Be the first to comment.